Skip to content

Nuvation Bio NUVB Cumulative Cost Basis

Cumulative Cost Basis at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Tango Therapeutics logo
Tango TherapeuticsTNGX
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's cumulative cost basis?
Nuvation Bio (NUVB) reported cumulative cost basis of $460.68M in Q4 2025.
How has Nuvation Bio's cumulative cost basis changed year-over-year?
Nuvation Bio's cumulative cost basis decreased by 3.7% year-over-year, from $478.48M to $460.68M.
What is the long-term trend for Nuvation Bio's cumulative cost basis?
Over 5 years (2020 to 2025), Nuvation Bio's cumulative cost basis has grown at a 18.8% compound annual growth rate (CAGR), from $194.84M to $460.68M.